Cure My Disease

Don't miss your cure!

 Log in / Sign up

Will a tiny sensor boost Well-Being in type 2 diabetes?

NCT ID NCT06716671

Symptom relief Sponsor: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This study asks whether using a continuous glucose monitor (CGM) — a small sensor worn under the skin that tracks blood sugar levels in real time — can improve quality of life for adults with type 2 diabetes. Participants will use the device for 12 months and complete questionnaires about diabetes-related distress, fear of low blood sugar, and overall well-being. The goal is to see if CGM not only helps control glucose but also eases the daily burden of managing diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
continuous glucose monitoring (CGM) device
What this could lead to
If CGM improves quality of life and glucose control, it could support wider funding and access to these devices for more people with type 2 diabetes.
What could go wrong
This is an observational study without a comparison group, so any improvements might be due to other factors. Results depend on participants consistently using the device.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

87 people

The number who actually took part.

Started

Sep 2024

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population is adults in an industrialised country with a diagnosis of type 2 diabetes with intensive insulin regimen who will start using a CGM sensor. Participants will be recruited from primary care centres in the Camp de Tarragona health region following inclusion and exclusion criteria. Depending on the location of the primary care centre, the population may be from an urban, semi-urban, or rural setting.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Treatment with intensive insulin therapy (basal bolus regimen with 3 or more daily doses of insulin). * Perform 6 or more daily capillary glycaemia determinations. * Be willing to use a CGM device for at least 70% of the time. * Undergo training on the use of the CGM device by the centre's CGM referent. * Agree to participate in the study. Exclusion Criteria: * Cognitive impairment measured by Pfeiffer test with a score of 3 or more errors. * Previous use of a CGM device. * Pregnancy. * Being institutionalised. * Having participated in another research study related to diabetes mellitus within the last year. * Not having proper handling of the CGM device: inability to download glycaemic control data, inability to keep the sensor attached to the skin, not understanding how it works, etc.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Continuous glucose monitoring are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypoglycemia Patient Satisfaction type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Continuous glucose monitoring Quality of life Type 2 diabetes mellitus (T2DM)

Contacts and locations

Locations

  • IDIAP Jordi Gol

    Barcelona, Barcelona, 08007, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.